Real-World data reveals how palbociclib works in everyday breast cancer care
NCT ID NCT04498481
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviewed medical records of women with advanced or metastatic HR+/HER2- breast cancer who received Palbociclib combined with hormone therapy in community clinics. The goal was to see how doctors actually prescribe these drugs, how long patients stay on treatment, and what outcomes like survival and side effects occur. It was an observational study, not a test of a new drug, so no direct treatment was given.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer United States
New York, New York, 10017, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?